InvestorsHub Logo
Followers 2543
Posts 250738
Boards Moderated 34
Alias Born 05/06/2014

Re: HighHoeSilverado post# 30749

Monday, 01/26/2015 12:50:52 PM

Monday, January 26, 2015 12:50:52 PM

Post# of 144814
Check out the news today

http://client.irwebkit.com/Nuvilex/news/2434100

This preclinical study will be conducted by Translational Drug Development (TD2) in the United States. Pancreatic cancer expert Dr. Daniel D. Von Hoff is the Chief Development Officer of TD2 and a principal architect of the study. It is expected that the study will begin in approximately two weeks.

"Patience, persistence and perspiration make an unbeatable combination for success."

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News